logo
  

Former CEO Of Exelon, Chris Crane, Passes Away At 65

Former chief executive officer of Exelon, Chris Crane, passed away at the age of 65. He died on April 13 in Chicago. He served as the company's president and chief executive officer from 2012 until his retirement in December 2022, the company said in a statement on Sunday.

Exelon noted that Crane steered the company through several transformational milestones including the successful mergers with Constellation Energy in 2012 and Pepco Holdings in 2016, creating the largest utility business by customer count, and the later creation of a standalone transmission and delivery company with the spinoff of the generation and retail energy business as Constellation Energy in 2022.

Chris Crane joined Exelon (then Unicom Corporation) in 1998 and was named chief nuclear officer in 2004. He was named president of Exelon Generation in 2007.

Chris Crane held several key industry roles throughout his career, including chair of the Edison Electric Institute, the Institute of Nuclear Power Operations, and the Nuclear Energy Institute. He also served as chair of the board of Chicago's Museum of Science and Industry and was a member of the board of the Economic Club of Washington, DC.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Automajor General Motors plans to end production of its gasoline-powered Chevrolet Malibu car later this year as it prepares to produce new electric vehicles, reports said. Chevy Malibu, which was launched in 1964, has since been sold more than 10 million in numbers. The Malibu will end its production in November. Ride-hailing and delivery platform Uber Technologies, Inc. (UBER) reported Wednesday a net loss for the first quarter that sharply widened from last year, hurt by a huge net unrealized loss related to the revaluation of Uber's equity investments. Loss per share for the quarter missed analysts' expectations, while quarterly revenues topped it. Shares of Siemens Energy AG were gaining more than 12 percent in German trading after the company on Wednesday raised its outlook for fiscal 2024 after reporting a profit in its second quarter, compared to last year's loss, amid positive market environment. Meanwhile, second-quarter orders were lower than last year, and the company maintained annual earnings forecast.

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
Follow RTT